XCUR (XCUR): a likely value trap?

Avoid — this is a near-shell company with $2M in equity, a Nasdaq delisting threat, and a history of repeated reverse splits to survive.

⚠ TRAP Fundamentals28/100

Down 100% from its all-time high of $862.50 — now $1.89

Why XCUR dropped

Exicure abandoned its original nucleic-acid drug business, pivoted via a 2025 acquisition into an early-stage blood cancer drug (burixafor), and is now a roughly $11-18 million market cap micro-cap burning cash with no approved products or revenue.

Fwd P/E -2.5Op margin 0.0%Rev growth —Debt/equity 1.0%Analyst upside —

How this scored 28/100 ❌ fails 3 hard checks

❌ Fails 3 hard checks — these are pass/fail and override the score entirely.

❌ Makes money not profitable (and no credible path to profit)

❌ Generates cash burns cash (free cash flow $-4M)

✅ Not drowning in debt Debt/equity 1.0% (limit 200%)

❌ Can pay its bills can't cover 12 months of bills (current ratio 0.79)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 0/25

Operating margin 0.0% 0/9

Net profit margin 0.0% 0/8

Return on equity -145.2% 0/8

Growth Is it getting bigger, or dying? 13/25

Revenue growth unknown 3/9

Earnings growth unknown 2/8

Expected profit change 51.0% 8/8

Value Is it cheap right now? 5/25

Forward P/E -2.5 0/10

PEG ratio unknown 2/8

Analyst target upside unknown 2/7

Balance sheet Will it survive? 10/25

Debt / equity 1.0% 10/10

Current ratio 0.8 0/8

Free cash flow $-4M 0/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for XCUR — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-07-21. Research only — not financial advice.